Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 31-May-24 4:56 PM View:  | Hamilton Thomas Edward Director | Larimar Therapeutics, Inc. (LRMR) | 16-Feb-24 | Market Purchase | 57,208 | $8.74 | $499,998.00 | 9% 667.02K to 724.23K | 5% |
| 16-Feb-24 2:37 PM View: | Flynn James E Director 10% Owner | Larimar Therapeutics, Inc. (LRMR) | 16-Feb-24 | Market Purchase | 4,290,620 | $8.74 | $37,500,000.00 | 25% 16.94M to 21.23M | 5% |
| 15-Feb-24 4:21 PM View: | Thomas Frank E Director | Larimar Therapeutics, Inc. (LRMR) | 14-Feb-24 | Purchase | 2,000 | $11.00 | $22,000.00 | 100% 0 to 2.0K | |
| 19-Jan-24 4:33 PM View: | Shankar Gopi Chief Development Officer | Larimar Therapeutics, Inc. (LRMR) | 17-Jan-24 | Grant | 22,500 | -- | -- | 450% 5.0K to 27.5K | |
| 19-Jan-24 4:31 PM View: | Ben-Maimon Carole President and CEO Director | Larimar Therapeutics, Inc. (LRMR) | 17-Jan-24 | Grant | 66,125 | -- | -- | 25% 266.83K to 332.95K | |
| 19-Jan-24 4:31 PM View: | Clayton Russell Chief Medical Officer | Larimar Therapeutics, Inc. (LRMR) | 17-Jan-24 | Grant | 22,500 | -- | -- | 100% 0 to 22.5K | |
| 19-Jan-24 4:32 PM View: | Celano Michael Chief Financial Officer | Larimar Therapeutics, Inc. (LRMR) | 17-Jan-24 | Grant | 31,250 | -- | -- | 28% 112.75K to 144.0K | |
| 08-Dec-23 4:08 PM View: | Shankar Gopi Chief Development Officer | Larimar Therapeutics, Inc. (LRMR) | 07-Dec-23 | Private Purchase | 5,000 | $3.73 | $18,661.50 | 100% 0 to 5.0K | |
| 18-May-23 2:13 PM View: | Ben-Maimon Carole President and CEO Director | Larimar Therapeutics, Inc. (LRMR) | 17-May-23 | Private Purchase | 5,000 | $3.70 | $18,525.00 | 2% 261.83K to 266.83K | |
| 18-May-23 2:13 PM View: | Celano Michael Chief Financial Officer | Larimar Therapeutics, Inc. (LRMR) | 17-May-23 | Private Purchase | 5,000 | $3.73 | $18,631.50 | 5% 107.75K to 112.75K | |
| 18-May-23 2:12 PM View: | Truitt Joseph Director | Larimar Therapeutics, Inc. (LRMR) | 17-May-23 | Private Purchase | 2,750 | $3.73 | $10,257.50 | 100% 0 to 2.75K | |
| 02-Feb-23 8:16 PM View: | Celano Michael Chief Financial Officer | Larimar Therapeutics, Inc. (LRMR) | 31-Jan-23 | Grant | 76,000 | -- | -- | 239% 31.75K to 107.75K | |
| 02-Feb-23 8:15 PM View: | Ben-Maimon Carole President and CEO Director | Larimar Therapeutics, Inc. (LRMR) | 31-Jan-23 | Grant | 205,000 | -- | -- | 361% 56.83K to 261.83K | |
| 20-Sep-22 6:54 AM View: | Hamilton Thomas Edward Director | Larimar Therapeutics, Inc. (LRMR) | 16-Sep-22 | Private Purchase | 317,460 | $3.15 | $999,999.00 | 91% 349.56K to 667.02K | |
| 19-Sep-22 7:00 AM View: | Ben-Maimon Carole President and CEO Director | Larimar Therapeutics, Inc. (LRMR) | 16-Sep-22 | Private Purchase | 31,746 | $3.15 | $99,999.90 | 127% 25.08K to 56.83K | |
| 20-Sep-22 8:31 PM View: | Flynn James E Director 10% Owner | Larimar Therapeutics, Inc. (LRMR) | 16-Sep-22 | Private Purchase | 11,111,100 | $3.15 | $35,000,000.00 | 191% 5.83M to 16.94M | |
| 19-Sep-22 7:00 AM View: | Celano Michael Chief Financial Officer | Larimar Therapeutics, Inc. (LRMR) | 16-Sep-22 | Private Purchase | 31,746 | $3.15 | $99,999.90 | 100% 0 to 31.75K | |
| 02-Jul-21 10:00 PM View: | Flynn James E Director 10% Owner | Larimar Therapeutics, Inc. (LRMR) | 30-Jun-21 | Market Purchase | 685,710 | $8.75 | $5,999,960.00 | 13% 5.14M to 5.83M | 11% |
| 30-Jun-20 5:00 PM View: | Ben-Maimon Carole President and CEO Director | Larimar Therapeutics, Inc. (LRMR) | 26-Jun-20 | Acquisition (other) | 25,083 | -- | -- | 100% 0 to 25.08K | |
| 30-Jun-20 5:02 PM View: | Hamilton Thomas Edward Director | Larimar Therapeutics, Inc. (LRMR) | 26-Jun-20 | Acquisition (other) | 133,420 | -- | -- | 100% 133.42K to 266.84K | |
| 30-Jun-20 5:02 PM View: | Hamilton Thomas Edward Director | Larimar Therapeutics, Inc. (LRMR) | 26-Jun-20 | Acquisition (other) | 159,433 | -- | -- | 60% 266.84K to 426.27K | |
| 30-Jun-20 5:01 PM View: | Chondrial Therapeutics Hold... 10% Owner | Larimar Therapeutics, Inc. (LRMR) | 26-Jun-20 | Disposition (other) | 6,091,240 | -- | -- | (100%) 6.09M to 8 | |
| 28-Jan-19 7:01 PM View: | Lamattina John L Director | Larimar Therapeutics, Inc. (LRMR) | 24-Jan-19 | Grant | 10,844 | $4.38 | $47,496.70 | 53% 20.53K to 31.38K | 195% |
| 28-Jan-19 7:01 PM View: | Perez Robert J Director | Larimar Therapeutics, Inc. (LRMR) | 24-Jan-19 | Grant | 4,423 | $4.38 | $19,372.70 | 68% 6.46K to 10.89K | 195% |
| 02-Jul-18 4:01 PM View: | Atlas Venture Fund Vii L P 10% Owner | Larimar Therapeutics, Inc. (LRMR) | 29-Jun-18 | Disposition (other) | 1,360,870 | -- | -- | (28%) 4.87M to 3.51M | |
| 29-Jun-18 7:01 PM View: | Hughes Thomas E. See Remarks Director | Larimar Therapeutics, Inc. (LRMR) | 28-Jun-18 | Market Sale (Planned) | 32,000 | $10.00 | $320,000.00 | (20%) 157.25K to 125.25K | (29%) |
| 09-Mar-18 6:00 PM View: | Hughes Thomas E. See Remarks Director | Larimar Therapeutics, Inc. (LRMR) | 07-Mar-18 | Market Sale (Planned) | 5,000 | $10.00 | $50,000.00 | (3%) 162.25K to 157.25K | (29%) |
| 05-Jan-18 5:02 PM View: | Daniel Thomas O Director | Larimar Therapeutics, Inc. (LRMR) | 03-Jan-18 | Grant | 8,687 | $5.18 | $44,998.70 | 81% 10.77K to 19.45K | 150% |
| 05-Jan-18 5:01 PM View: | Lamattina John L Director | Larimar Therapeutics, Inc. (LRMR) | 03-Jan-18 | Grant | 9,169 | $5.18 | $47,495.40 | 81% 11.36K to 20.53K | 150% |
| 17-Oct-17 5:11 PM View: | Heller Frances K Director | Larimar Therapeutics, Inc. (LRMR) | 13-Oct-17 | Market Purchase | 10,000 | $3.90 | $38,988.00 | 26% 37.96K to 47.96K | 231% |
| 12-Jul-17 4:05 PM View: | Kim Dennis D Chief Medical Officer | Larimar Therapeutics, Inc. (LRMR) | 11-Jul-17 | Market Purchase | 10,000 | $3.39 | $33,900.00 | 87% 11.44K to 21.44K | 281% |
| 15-May-17 8:22 PM View: | Hughes Thomas E. President and CEO Director | Larimar Therapeutics, Inc. (LRMR) | 11-May-17 | Option Exercise | 93,211 | $0.80 | $74,673.40 | 145% 64.16K to 157.37K | |
| 11-May-17 6:59 PM View: | Kim Dennis D Chief Medical Officer | Larimar Therapeutics, Inc. (LRMR) | 11-May-17 | Market Purchase | 9,800 | $4.40 | $43,120.00 | 596% 1.64K to 11.44K | 193% |
| 11-May-17 6:59 PM View: | Kim Dennis D Chief Medical Officer | Larimar Therapeutics, Inc. (LRMR) | 10-May-17 | Market Purchase | 200 | $4.40 | $880.00 | 14% 1.44K to 1.64K | 193% |
| 14-Feb-17 8:14 PM View: | Daniel Thomas O Director | Larimar Therapeutics, Inc. (LRMR) | 13-Feb-17 | Grant | 10,765 | $4.18 | $44,997.70 | 100% 0 to 10.77K | 209% |
| 14-Feb-17 8:07 PM View: | Lamattina John L Director | Larimar Therapeutics, Inc. (LRMR) | 13-Feb-17 | Grant | 11,363 | $4.18 | $47,497.30 | 100% 0 to 11.36K | 209% |
| 20-Dec-16 5:02 PM View: | Heller Frances K Director | Larimar Therapeutics, Inc. (LRMR) | 19-Dec-16 | Market Purchase | 10,000 | $3.23 | $32,290.00 | 50% 20.0K to 30.0K | 289% |
| 17-Nov-16 5:00 PM View: | Heller Frances K Director | Larimar Therapeutics, Inc. (LRMR) | 15-Nov-16 | Market Purchase | 10,000 | $3.54 | $35,434.00 | 100% 10.0K to 20.0K | 246% |
| 31-Aug-16 4:15 PM View: | Hughes Thomas E. President and CEO Director | Larimar Therapeutics, Inc. (LRMR) | 29-Aug-16 | Market Purchase | 10,000 | $3.00 | $29,987.00 | 19% 53.94K to 63.94K | 309% |
| 26-Jul-16 5:10 PM View: | Allen Patricia L Chief Financial Officer | Larimar Therapeutics, Inc. (LRMR) | 26-Jul-16 | Market Purchase | 8,200 | $3.15 | $25,830.00 | 71% 11.59K to 19.79K | 290% |
| 26-Jul-16 5:10 PM View: | Allen Patricia L Chief Financial Officer | Larimar Therapeutics, Inc. (LRMR) | 25-Jul-16 | Market Purchase | 7,800 | $3.08 | $24,031.80 | 206% 3.79K to 11.59K | 299% |
| 26-Jul-16 5:09 PM View: | Heller Frances K Director | Larimar Therapeutics, Inc. (LRMR) | 22-Jul-16 | Market Purchase | 10,000 | $2.99 | $29,900.00 | 100% 0 to 10.0K | 311% |
| 26-Jul-16 5:14 PM View: | Hughes Thomas E. President and CEO Director | Larimar Therapeutics, Inc. (LRMR) | 22-Jul-16 | Market Purchase | 5,000 | $3.02 | $15,104.00 | 10% 48.94K to 53.94K | 306% |
| 26-Jul-16 5:14 PM View: | Hughes Thomas E. President and CEO Director | Larimar Therapeutics, Inc. (LRMR) | 22-Jul-16 | Option Exercise | 25,000 | $0.75 | $18,750.00 | 104% 23.94K to 48.94K | |
| 01-Aug-16 7:14 PM View: | Flynn James E 10% Owner | Larimar Therapeutics, Inc. (LRMR) | 20-Jul-16 | Market Sale | 1,341,500 | $3.31 | $4,442,780.00 | (44%) 3.06M to 1.71M | (271%) |
| 04-Apr-16 9:00 PM View: | McDonough Cameron Geoffrey Director | Larimar Therapeutics, Inc. (LRMR) | 01-Apr-16 | Disposition | 4,424 | $7.91 | $34,993.80 | (100%) 4.42K to 0 | |
| 17-Feb-16 2:02 PM View: | Flynn James E 10% Owner | Larimar Therapeutics, Inc. (LRMR) | 12-Feb-16 | Market Purchase | 64,545 | $6.25 | $403,187.00 | 2% 2.99M to 3.06M | 97% |
| 11-Feb-16 8:21 PM View: | Flynn James E 10% Owner | Larimar Therapeutics, Inc. (LRMR) | 11-Feb-16 | Market Purchase | 2,344 | $6.19 | $14,505.60 | < 1% 2.99M to 2.99M | 98% |
| 11-Feb-16 8:21 PM View: | Flynn James E 10% Owner | Larimar Therapeutics, Inc. (LRMR) | 10-Feb-16 | Market Purchase | 151,226 | $6.23 | $942,486.00 | 5% 2.84M to 2.99M | 97% |
| 11-Feb-16 8:21 PM View: | Flynn James E 10% Owner | Larimar Therapeutics, Inc. (LRMR) | 09-Feb-16 | Market Purchase | 113,923 | $5.73 | $652,676.00 | 4% 2.72M to 2.84M | 114% |
